7 mmol/L) are considered to be normal, while values between 150–199 mg/dL (1.7-2.25 mmol/L) define borderline hypertriglyceridemia, 200–499 mg/dL
(2.25-5.65 mmol/L) define high TGs, and >500 mg/dL (>5.65 mmol/L) define very high TGs. Also serum LDL-C concentrations were similar across the groups, with a mean value of 127 mg/dL. Some significant differences between the treatment and placebo groups at baseline were observed for HDL-C, BMI and the omega-3 index (Table 2); nonetheless, overall, the subjects had a low omega-3 index (between 3.5-4%) and BMI was around 30 kg/m2. Only three participants withdrew from the study (Fig. 1). Overall, krill oil supplementation was well tolerated in all groups and no serious adverse events related to study product occurred during the study. There were two subjects with Selleckchem Ixazomib unrelated serious adverse events, including asthma and cellulitis. Other incidences of non-serious adverse events that could Mitomycin C in vivo possibly be related
to study product intake were: hypertension (1), soft stool (2), flatulence (1), upset stomach (3), gastrointestinal discomfort (1), decreased appetite (1), headache (1), taste change (1), diarrhea (4), fishy burps (1), heartburn (1) and intermittent belching (1). Body weight and blood pressure remained unchanged during the 12-week study compared to baseline values in all five groups. Compliance was confirmed by measuring the omega-3 index (Table 3). The omega-3 index levels increased significantly in all treatment groups after both 6 and 12 weeks of krill oil supplementation, whereas the placebo group remained unchanged. The omega-3 index changed by −3, 5, 12, 19 and 52% from baseline in the placebo, 0.5, 1, 2 or 4 g krill oil groups, Y-27632 concentration respectively, after 6 weeks of supplementation. The corresponding changes after 12 weeks were – 3, 8, 18, 29, and 73%. After 6 weeks,
subjects in the 1, 2 and 4 g/day krill oil groups revealed a 18.6 to 19.9 mg/dL decrease in fasting serum TG levels, whereas the 0.5 g/day group showed a 13.1 mg/dL decrease, when compared to baseline (Table 4). However, a significant change in TG levels was lost at 12 weeks in all groups. Still, after 12 weeks of supplementation, subjects receiving krill oil demonstrated a 10.2% decrease in fasting serum TG values, when assessed by a pooled group- and time-independent approach that included all the measurements after 6 and 12 weeks in the 0.5, 1, 2 and 4 g/day krill oil groups compared to placebo (Fig. 2). The changes (%) from baseline in TG levels amongst subjects supplemented with krill oil were significant relative to the (%) change from baseline in TGs in the placebo group (p = 0.0389). The change from baseline in fasting TGs was 3.9% in the placebo group and −6.3% in the krill oil group. Total cholesterol (Fig. 3), LDL-C (Fig. 4), and HDL-C (Fig. 5) at 6 weeks and at 12 weeks remained unchanged relative to baseline in the placebo and krill oil groups.